
The FDA has accepted for review a supplemental new drug application submitted by Sirion Therapeutics Inc., which seeks market approval of difluprednate ophthalmic emulsion 0.05% (Durezol) for the treatment of endogenous anterior uveitis, according to a statement issued by Sirion.
